Beyond Trial Dashboard

Dummy Project

CNS-119

Biomarker logistics, screen failure, caregiver burden, and endpoint reliability.

NeurologyPhase IIBiomarker-enriched CNSPlanning

Project Story

What readers should notice

CNS-119 is written as a case a working PM can recognize, not as a sterile protocol summary. The project sits in Neurology as a Biomarker-enriched CNS study, but the real teaching point is this: biomarker screening, caregiver burden, subjective assessment, and high screen failure make the PM protect interpretability before enrollment promises harden. When readers compare CNS-119 with their own project, they should look for the same pressure points: what the protocol assumes, what sites can actually do, what vendors must prove, what data must remain credible, what safety or ethics concern could change the plan, and what Daniel Liang's team would ask before accepting a green dashboard as truth.

Lifecycle Coverage

Book Mentions

How to read this case

Look for the moment when ordinary project language stops being enough: a date slips, an assumption fails, a vendor signal loses meaning, or a clinical concern changes the work. Then follow the chapter links, toolkit examples, glossary terms, and packet artifacts to compare this fictional pressure pattern with a real project you manage.

Initiation Packet